Published by Josh White on 11th December 2023
(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Society of Hematology (ASH) annual meeting, it announced on Monday.
URL: http://www.digitallook.com/dl/news/story/33963740/...